Novartis Ag (NVS) Notes Payables (2017 - 2025)

Novartis Ag (NVS) has 9 years of Notes Payables data on file, last reported at $682.0 million in Q4 2025.

• Quarterly Notes Payables rose 6.23% year-over-year to $682.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $682.0 million (up 6.23% YoY) and the FY2025 annual result came in at $682.0 million, up 6.23% from the prior year.
• Notes Payables advanced to $682.0 million in Q4 2025 per NVS's latest filing, from $642.0 million in the prior quarter.
• The five-year high for Notes Payables was $899.0 million in Q4 2021, with the low at $624.0 million in Q4 2023.
• Average Notes Payables over 5 years is $742.0 million, with a median of $682.0 million recorded in 2025.
• Year-over-year, Notes Payables decreased 27.69% in 2023 and increased 6.23% in 2025.
• Novartis Ag's Notes Payables stood at $899.0 million in 2021, then fell by 4.0% to $863.0 million in 2022, then fell by 27.69% to $624.0 million in 2023, then climbed by 2.88% to $642.0 million in 2024, then increased by 6.23% to $682.0 million in 2025.
• Business Quant data shows NVS's Notes Payables at $682.0 million in Q4 2025, $642.0 million in Q4 2024, and $624.0 million in Q4 2023.